serrat-14-ene-3,21-diol: from the stem bark of Erythrina eriotriocha; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Erythrina | genus | A genus of leguminous shrubs or trees, mainly tropical, yielding useful compounds such as ALKALOIDS and PLANT LECTINS.[MeSH] | Fabaceae | The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 164947 |
| CHEMBL ID | 510572 |
| SCHEMBL ID | 5487576 |
| MeSH ID | M0187396 |
| Synonym |
|---|
| serratenediol |
| 2239-24-9 |
| CHEMBL510572 |
| c(14a)-homo-27-norgammacer-14-ene-3,21-diol, (3beta,21alpha)- |
| serrat-14-ene-3,21-diol |
| serrat-14-ene-3beta,21alpha-diol |
| cathaya d |
| SCHEMBL5487576 |
| FS-9612 |
| DTXSID10945039 |
| 4,4,6a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,6,6a,7,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1h-cyclohepta[1,2-a:5,4-a']dinaphthalene-3,11-diol |
| (3s,6r,8s,11r,12s,15s,16r,19s,21r)-3,7,7,11,16,20,20-heptamethylpentacyclo[13.8.0.03,12.06,11.016,21]tricos-1(23)-ene-8,19-diol |
| AKOS040762335 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID361092 | Inhibition of Candida albicans secreted aspartic protease | 2002 | Journal of natural products, Jul, Volume: 65, Issue:7 | Natural products inhibiting Candida albicans secreted aspartic proteases from Lycopodium cernuum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||